Clinical manifestations and long-term outcome of anti-Jo1 antisynthetase patients in a large cohort of Spanish patients from the GEAS-IIM group

Seminars in Arthritis and Rheumatism

Volumn 46, Issue 2, 2016, Pages 225-231

  Trallero Araguás, Ernesto ^a   Grau Junyent, Josep María ^b   Labirua Iturburu, Anne ^a   García Hernández, Francisco José ^c   Monteagudo Jiménez, Manuel ^d   Fraile Rodriguez, Guadalupe ^e   Les Bujanda, Iñigo ^f   Rodriguez Carballeira, Mónica ^g   Sáez Comet, Luis ^h   Selva O'Callaghan, Albert ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d HOSPITAL DE SABADELL   (Spain)

^e HOSPITAL RAMÓN Y CAJAL   (Spain)

^f HOSPITAL DE CRUCES   (Spain)

^g HOSPITAL MÚTUA DE TERRASSA   (Spain)

^h HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

Author keywords

Anti Jo1 antibodies; Antisynthetase syndrome; Idiopathic Inflammatory myopathies; Myositis specific autoantibody

Indexed keywords

AMINO ACID TRANSFER RNA LIGASE; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; JO 1 ANTIBODY; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID; OXYGEN; RITUXIMAB; STEROID; TACROLIMUS; ANTINUCLEAR ANTIBODY; JO-1 ANTIBODY;

ADULT; AGED; ANTISYNTHETASE SYNDROME; ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DYSPNEA; FEMALE; FOLLOW UP; FORCED VITAL CAPACITY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG FUNCTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYOSITIS; NEOPLASM; OXYGEN THERAPY; PHENOTYPE; POLYARTHRITIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPANIARD; SURVIVAL RATE; VERY ELDERLY; ARTHRITIS; COMPLICATION; IMMUNOLOGY; REGISTER;

ADULT; AGED; ANTIBODIES, ANTINUCLEAR; ARTHRITIS; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MYOSITIS; REGISTRIES; RETROSPECTIVE STUDIES;

EID: 84964579615     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2016.03.011     Document Type: Article

References (34)

1. [1] Marguerie, C., Bunn, C.C., Beynon, H.L., Bernstein, R.M., Hughes, J.M., So, A.K., et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med 77 (1990), 1019–1038.
2. [2] Hamaguchi, Y., Fujimoto, M., Matsushita, T., Kaji, K., Komura, K., Hasegawa, M., et al. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS One, 8, 2013, e60442.
3. [3] Wasicek, C.A., Reichlin, M., Montes, M., Raghu, G., Polymyositis and interstitial lung disease in a patient with anti-Jo1 prototype. Am J Med 76:3 (1984), 538–544.
4. [4] Dalakas, M.C., Hohlfeld, R., Polymyositis and dermatomyositis. Lancet 362 (2003), 971–982.
5. [5] Hervier, B., Devilliers, H., Stanciu, R., Meyer, A., Uzunhan, Y., Masseau, A., et al. Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmun Rev 12 (2012), 210–217.
6. [6] Aggarwal, R., Cassidy, E., Fertig, N., Koontz, D.C., Lucas, M., Ascherman, D.P., et al. Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis 73 (2014), 227–232.
7. [7] Tillie-Leblond, I., Wislez, M., Valeyre, D., Crestani, B., Rabbat, A., Israel-Biet, D., et al. Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. Thorax 63 (2008), 53–59.
8. [8] Koreeda, Y., Higashimoto, I., Yamamoto, M., Takahashi, M., Kaji, K., Fujimoto, M., et al. Clinical and pathological findings of interstitial lung disease patients with anti-aminoacyl-tRNA synthetase autoantibodies. Intern Med 49 (2010), 361–369.
9. [9] Marie, I., Josse, S., Hatron, P.Y., Dominique, S., Hachulla, E., Janvresse, A., et al. Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome. Arthritis Care Res (Hoboken ) 65 (2013), 800–808.
10. [10] Cavagna, L., Nuno, L., Scire, C.A., Govoni, M., Longo, F.J., Franceschini, F., et al. Clinical spectrum time course in anti Jo-1 positive antisynthetase syndrome: results from an international retrospective multicenter study. Medicine (Baltimore), 94, 2015, e1144.
11. [11] Johnson, C., Connors, G.R., Oaks, J., Han, S., Truong, A., Richardson, B., et al. Clinical and pathologic differences in interstitial lung disease based on antisynthetase antibody type. Respir Med 108 (2014), 1542–1548.
12. [12] Bohan, A., Peter, J.B., Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292 (1975), 344–347.
13. [13] Bohan, A., Peter, J.B., Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292 (1975), 403–407.
14. [14] Sontheimer, R.D., Cutaneous features of classic dermatomyositis and amyopathic dermatomyositis. Curr Opin Rheumatol 11:6 (1999), 475–482.
15. [15] Raghu, G., Collard, H.R., Egan, J.J., Martinez, F.J., Behr, J., Brown, K.K., et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183 (2011), 788–824.
16. [16] Selva-O'Callaghan, A., Trallero-Araguas, E., Grau-Junyent, J.M., Labrador-Horrillo, M., Malignancy and myositis: novel autoantibodies and new insights. Curr Opin Rheumatol 22 (2010), 627–632.
17. [17] Marie, I., Hatron, P.Y., Dominique, S., Cherin, P., Mouthon, L., Menard, J.F., et al. Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody. Semin Arthritis Rheum 41 (2012), 890–899.
18. [18] Lefevre, G., Meyer, A., Launay, D., Machelart, I., DeBandt, M., Michaud, J., et al. Seronegative polyarthritis revealing antisynthetase syndrome: a multicentre study of 40 patients. Rheumatology (Oxford), 2014.
19. [19] Schmidt, W.A., Wetzel, W., Friedlander, R., Lange, R., Sorensen, H.F., Lichey, H.J., et al. Clinical and serological aspects of patients with anti-Jo-1 antibodies—an evolving spectrum of disease manifestations. Clin Rheumatol 19 (2000), 371–377.
20. [20] Hervier, B., Benveniste, O., Clinical heterogeneity and outcomes of antisynthetase syndrome. Curr Rheumatol Rep, 15, 2013, 349.
21. [21] Saketkoo, L.A., Mittoo, S., Huscher, D., Khanna, D., Dellaripa, P.F., Distler, O., et al. Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. Thorax 69 (2014), 428–436.
22. [22] Raghu, G., Collard, H.R., Anstrom, K.J., Flaherty, K.R., Fleming, T.R., King, T.E. Jr., et al. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med 185 (2012), 1044–1048.
23. [23] Kang, E.H., Lee, E.B., Shin, K.C., Im, C.H., Chung, D.H., Han, S.K., et al. Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology (Oxford) 44 (2005), 1282–1286.
24. [24] Love, L.A., Leff, R.L., Fraser, D.D., Targoff, I.N., Dalakas, M., Plotz, P.H., et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 70 (1991), 360–374.
25. [25] Chen, Y.J., Wu, C.Y., Shen, J.L., Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study. Br J Dermatol 144 (2001), 825–831.
26. [26] Amoura, Z., Duhaut, P., Huong, D.L., Wechsler, B., Costedoat-Chalumeau, N., Frances, C., et al. Tumor antigen markers for the detection of solid cancers in inflammatory myopathies. Cancer Epidemiol Biomarkers Prev 14 (2005), 1279–1282.
27. [27] Chinoy, H., Fertig, N., Oddis, C.V., Ollier, W.E., Cooper, R.G., The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 66 (2007), 1345–1349.
28. [28] Rozelle, A., Trieu, S., Chung, L., Malignancy in the setting of the anti-synthetase syndrome. J Clin Rheumatol 14 (2008), 285–288.
29. [29] Legault, D., McDermott, J., Crous-Tsanaclis, A.M., Boire, G., Cancer-associated myositis in the presence of anti-Jo1 autoantibodies and the antisynthetase syndrome. J Rheumatol 35 (2008), 169–171.
30. [30] Marie, I., Hatron, P.Y., Cherin, P., Hachulla, E., Diot, E., Vittecoq, O., et al. Functional outcome and prognostic factors in anti-Jo1 patients with antisynthetase syndrome. Arthritis Res Ther, 15, 2013, R149.
31. [31] Castaneda-Pomeda, M., Prieto-Gonzalez, S., Grau, J.M., Antisynthetase syndrome and malignancy: our experience. J Clin Rheumatol, 17, 2011, 458.
32. [32] Stanciu, R., Guiguet, M., Musset, L., Touitou, D., Beigelman, C., Rigolet, A., et al. Antisynthetase syndrome with anti-Jo1 antibodies in 48 patients: pulmonary involvement predicts disease-modifying antirheumatic drug use. J Rheumatol 39 (2012), 1835–1839.
33. [33] Vancsa, A., Csipo, I., Nemeth, J., Devenyi, K., Gergely, L., Danko, K., Characteristics of interstitial lung disease in SS-A positive/Jo-1 positive inflammatory myopathy patients. Rheumatol Int 29 (2009), 989–994.
34. [34] La, C.R., Lo, Mo. N.A., Locaputo, A., Dolzani, F., Trotta, F., In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease. Autoimmunity 39 (2006), 249–253.